Synopsis
Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-butyl-n-(2,6-dimethylphenyl)-2-piperidinecarboxamide
2. Bupivacain Janapharm
3. Bupivacain Rpr
4. Bupivacain-rpr
5. Bupivacaina Braun
6. Bupivacaine
7. Bupivacaine Anhydrous
8. Bupivacaine Carbonate
9. Bupivacaine Monohydrochloride, Monohydrate
10. Buvacaina
11. Carbostesin
12. Dolanaest
13. Marcain
14. Marcaine
15. Sensorcaine
16. Svedocain Sin Vasoconstr
1. Bupivacaine Hcl
2. 18010-40-7
3. 14252-80-3
4. Carbostesin
5. Vivacaine
6. Sensorcaine
7. Bupivacaine (hydrochloride)
8. 1-butyl-n-(2,6-dimethylphenyl)piperidine-2-carboxamide Hydrochloride
9. Marcain
10. Ah-2250
11. Bupivacaine Hydrochloride Anhydrous
12. Lac-43
13. Nsc-758631
14. 1-butyl-n-(2,6-dimethylphenyl)piperidine-2-carboxamide;hydrochloride
15. 2-piperidinecarboxamide, 1-butyl-n-(2,6-dimethylphenyl)-, Monohydrochloride
16. Win 11,318
17. Aka908p8j1
18. Chebi:31322
19. 1-butyl-n-(2,6-dimethylphenyl)-2-piperidinecarboxamide Monohydrochloride
20. Bloqueina
21. Xaracoll
22. 2-piperidinecarboxamide, 1-butyl-n-(2,6-dimethylphenyl)-, Hydrochloride (1:1)
23. (s)-bupivacaine Hydrochloride
24. Bicain
25. Marcaine Spinal
26. Smr000058218
27. (+-)-bupivacaine Hydrochloride
28. Bupivacaine Hydrochloride [jan]
29. Mnarcaine Hydrochloride
30. Einecs 241-917-8
31. Bupivacaine Hydrochloride Kit
32. Unii-aka908p8j1
33. Lac 43
34. Sr-05000001874
35. 1-butyl-n-(2,6-dimethylphenyl)-2-piperidinecarboxamide
36. Levobupivacaine Hydrochloride (anhydrous)
37. 2',6'-pipecoloxylidide, 1-butyl-, Hydrochloride
38. Sky 0302
39. Prestwick_894
40. 2',6'-pipecoloxylidide, 1-butyl-, Monohydrochloride
41. Ah 2250
42. Marcaine Hydrochloride Preservation Free
43. Bupivacain Hydrochloride
44. Bupivacaine Hydrochloride Preservation Free
45. Bupivacaini Hydrochloridum
46. Bupivacaine Hydrochloride Rs
47. Bupivacaine Monohydrochloride
48. Win 11318 Hcl
49. Schembl34374
50. Mls001361336
51. Mls002154259
52. Spectrum1503818
53. Bupivacaine-[d9] Hydrochloride
54. Chembl1200396
55. Dtxsid0030877
56. Chebi:77441
57. Hy-b0405a
58. Bupivacaine Hydrochloride(marcain)
59. Hms1568n12
60. Hms1922i12
61. Pharmakon1600-01503818
62. Bupivacaine Hydrochloride (marcain)
63. Act04725
64. Bcp22697
65. Bcp22708
66. Bupivacaine Hydrochloride (anhydrous)
67. Ccg-39367
68. Mfcd00078956
69. Nsc119660
70. Nsc758631
71. S2454
72. Bupivacaine Hydrochloride [mi]
73. Akos015889322
74. Bcp9000461
75. Fd-0235
76. Nsc 758631
77. Nsc-119660
78. Ncgc00095072-01
79. Ncgc00095072-02
80. Anhydrous Bupivacaine Hydrochloride
81. Bupivacaine Hydrochloride [who-dd]
82. Bupivacaine Hydrochloride, Anhydrous
83. B3925
84. Ft-0607564
85. Ft-0623287
86. Ft-0658830
87. Ft-0663897
88. Ft-0663899
89. Sw197015-3
90. 52b803
91. Bupivacaine Hydrochloride [usp Impurity]
92. J-011502
93. Q-100158
94. Sr-05000001874-3
95. Q27888209
96. 1-butyl-2-piperidylformo-2',6'-xylidide Hydrochloride
97. 2-piperidinecarboxamide,6-dimethylphenyl)-, Hydrochloride
98. 1-butyl-2-[(2,6-dimethylphenyl)carbamoyl]piperidinium Chloride
99. (+/-)-1-butyl-2',6'-pipecoloxylidide Monohydrochloride
100. Rac-1-butyl-2-[(2,6-dimethylphenyl)carbamoyl]piperidinium Chloride
101. Rac-1-butyl-n-(2,6-dimethylphenyl)piperidine-2-carboxamide Hydrochloride
102. 15233-43-9
| Molecular Weight | 324.9 g/mol |
|---|---|
| Molecular Formula | C18H29ClN2O |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 5 |
| Exact Mass | 324.1968412 g/mol |
| Monoisotopic Mass | 324.1968412 g/mol |
| Topological Polar Surface Area | 32.3 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 321 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 6 | |
|---|---|
| Drug Name | Bupivacaine hydrochloride |
| PubMed Health | Bupivacaine/Epinephrine (Injection) |
| Drug Classes | Anesthetic, Amino Amide Combination, Anesthetic, Local |
| Drug Label | Sensorcaine (bupivacaine HCl) injections are sterile isotonic solutions that contain a local anesthetic agent with and without epinephrine (as bitartrate) 1:200,000 and are administered parenterally by injection. See INDICATIONS AND USAGE for spe... |
| Active Ingredient | Bupivacaine hydrochloride |
| Dosage Form | Injectable |
| Route | injection; Spinal; Injection |
| Strength | 0.5%; 0.75%; 0.25% |
| Market Status | Prescription |
| Company | Sagent Agila; Hospira |
| 2 of 6 | |
|---|---|
| Drug Name | Marcaine |
| PubMed Health | Bupivacaine (Injection) |
| Drug Classes | Anesthetic, Local |
| Drug Label | MarcaineBupivacaine Hydrochloride Injection, USPMarcaineWith Epinephrine 1:200,000 (as bitartrate)Bupivacaine Hydrochloride and Epinephrine Injection, USP Rx onlyBupivacaine hydrochloride is 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylpheny... |
| Active Ingredient | Bupivacaine hydrochloride |
| Dosage Form | Injectable |
| Route | Spinal |
| Strength | 0.75% |
| Market Status | Prescription |
| Company | Hospira |
| 3 of 6 | |
|---|---|
| Drug Name | Sensorcaine |
| Drug Label | Sensorcaine (bupivacaine HCl) injections are sterile isotonic solutions that contain a local anesthetic agent with and without epinephrine (as bitartrate) 1:200,000 and are administered parenterally by injection. See INDICATIONS AND USAGE for spe... |
| Active Ingredient | Bupivacaine hydrochloride; epinephrine bitartrate |
| Dosage Form | Injectable |
| Route | Spinal; Injection |
| Strength | 0.5%; 0.0091mg/ml; 0.75%; 0.25% |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 4 of 6 | |
|---|---|
| Drug Name | Bupivacaine hydrochloride |
| PubMed Health | Bupivacaine/Epinephrine (Injection) |
| Drug Classes | Anesthetic, Amino Amide Combination, Anesthetic, Local |
| Drug Label | Sensorcaine (bupivacaine HCl) injections are sterile isotonic solutions that contain a local anesthetic agent with and without epinephrine (as bitartrate) 1:200,000 and are administered parenterally by injection. See INDICATIONS AND USAGE for spe... |
| Active Ingredient | Bupivacaine hydrochloride |
| Dosage Form | Injectable |
| Route | injection; Spinal; Injection |
| Strength | 0.5%; 0.75%; 0.25% |
| Market Status | Prescription |
| Company | Sagent Agila; Hospira |
| 5 of 6 | |
|---|---|
| Drug Name | Marcaine |
| PubMed Health | Bupivacaine (Injection) |
| Drug Classes | Anesthetic, Local |
| Drug Label | MarcaineBupivacaine Hydrochloride Injection, USPMarcaineWith Epinephrine 1:200,000 (as bitartrate)Bupivacaine Hydrochloride and Epinephrine Injection, USP Rx onlyBupivacaine hydrochloride is 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylpheny... |
| Active Ingredient | Bupivacaine hydrochloride |
| Dosage Form | Injectable |
| Route | Spinal |
| Strength | 0.75% |
| Market Status | Prescription |
| Company | Hospira |
| 6 of 6 | |
|---|---|
| Drug Name | Sensorcaine |
| Drug Label | Sensorcaine (bupivacaine HCl) injections are sterile isotonic solutions that contain a local anesthetic agent with and without epinephrine (as bitartrate) 1:200,000 and are administered parenterally by injection. See INDICATIONS AND USAGE for spe... |
| Active Ingredient | Bupivacaine hydrochloride; epinephrine bitartrate |
| Dosage Form | Injectable |
| Route | Spinal; Injection |
| Strength | 0.5%; 0.0091mg/ml; 0.75%; 0.25% |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
Anesthetics, Local
Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - 0.25%
USFDA APPLICATION NUMBER - 16964
DOSAGE - INJECTABLE;INJECTION - 0.25%;0.0091M...DOSAGE - INJECTABLE;INJECTION - 0.25%;0.0091MG/ML
USFDA APPLICATION NUMBER - 16964
DOSAGE - INJECTABLE;INJECTION - 0.5%
USFDA APPLICATION NUMBER - 16964
DOSAGE - INJECTABLE;INJECTION - 0.5%;0.0091MG...DOSAGE - INJECTABLE;INJECTION - 0.5%;0.0091MG/ML
USFDA APPLICATION NUMBER - 16964
DOSAGE - INJECTABLE;INJECTION - 0.75%
USFDA APPLICATION NUMBER - 16964
DOSAGE - INJECTABLE;INJECTION - 0.75%;0.0091M...DOSAGE - INJECTABLE;INJECTION - 0.75%;0.0091MG/ML
USFDA APPLICATION NUMBER - 16964
DOSAGE - INJECTABLE;INJECTION - 0.25%
USFDA APPLICATION NUMBER - 18304
DOSAGE - INJECTABLE;INJECTION - 0.5%
USFDA APPLICATION NUMBER - 18304
DOSAGE - INJECTABLE;INJECTION - 0.5%;0.0091MG...DOSAGE - INJECTABLE;INJECTION - 0.5%;0.0091MG/ML
USFDA APPLICATION NUMBER - 18304
DOSAGE - INJECTABLE;INJECTION - 0.75%
USFDA APPLICATION NUMBER - 18304
DOSAGE - INJECTABLE;INJECTION - 0.75%;0.0091M...DOSAGE - INJECTABLE;INJECTION - 0.75%;0.0091MG/ML
USFDA APPLICATION NUMBER - 18304
DOSAGE - INJECTABLE;INJECTION - 0.5%;0.0091MG...DOSAGE - INJECTABLE;INJECTION - 0.5%;0.0091MG/ML
USFDA APPLICATION NUMBER - 22046
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Parenteral
Fillers, Diluents & Binders
Topical
Co-Processed Excipients
Taste Masking
Film Formers & Plasticizers
Coating Systems & Additives
Controlled & Modified Release
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
92
PharmaCompass offers a list of Bupivacaine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Bupivacaine Hydrochloride manufacturer or Bupivacaine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Bupivacaine Hydrochloride manufacturer or Bupivacaine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Bupivacaine Hydrochloride API Price utilized in the formulation of products. Bupivacaine Hydrochloride API Price is not always fixed or binding as the Bupivacaine Hydrochloride Price is obtained through a variety of data sources. The Bupivacaine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Buvacaina manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Buvacaina, including repackagers and relabelers. The FDA regulates Buvacaina manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Buvacaina API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Buvacaina manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Buvacaina supplier is an individual or a company that provides Buvacaina active pharmaceutical ingredient (API) or Buvacaina finished formulations upon request. The Buvacaina suppliers may include Buvacaina API manufacturers, exporters, distributors and traders.
click here to find a list of Buvacaina suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Buvacaina DMF (Drug Master File) is a document detailing the whole manufacturing process of Buvacaina active pharmaceutical ingredient (API) in detail. Different forms of Buvacaina DMFs exist exist since differing nations have different regulations, such as Buvacaina USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Buvacaina DMF submitted to regulatory agencies in the US is known as a USDMF. Buvacaina USDMF includes data on Buvacaina's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Buvacaina USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Buvacaina suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Buvacaina Drug Master File in Japan (Buvacaina JDMF) empowers Buvacaina API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Buvacaina JDMF during the approval evaluation for pharmaceutical products. At the time of Buvacaina JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Buvacaina suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Buvacaina Drug Master File in Korea (Buvacaina KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Buvacaina. The MFDS reviews the Buvacaina KDMF as part of the drug registration process and uses the information provided in the Buvacaina KDMF to evaluate the safety and efficacy of the drug.
After submitting a Buvacaina KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Buvacaina API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Buvacaina suppliers with KDMF on PharmaCompass.
A Buvacaina CEP of the European Pharmacopoeia monograph is often referred to as a Buvacaina Certificate of Suitability (COS). The purpose of a Buvacaina CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Buvacaina EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Buvacaina to their clients by showing that a Buvacaina CEP has been issued for it. The manufacturer submits a Buvacaina CEP (COS) as part of the market authorization procedure, and it takes on the role of a Buvacaina CEP holder for the record. Additionally, the data presented in the Buvacaina CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Buvacaina DMF.
A Buvacaina CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Buvacaina CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Buvacaina suppliers with CEP (COS) on PharmaCompass.
A Buvacaina written confirmation (Buvacaina WC) is an official document issued by a regulatory agency to a Buvacaina manufacturer, verifying that the manufacturing facility of a Buvacaina active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Buvacaina APIs or Buvacaina finished pharmaceutical products to another nation, regulatory agencies frequently require a Buvacaina WC (written confirmation) as part of the regulatory process.
click here to find a list of Buvacaina suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Buvacaina as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Buvacaina API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Buvacaina as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Buvacaina and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Buvacaina NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Buvacaina suppliers with NDC on PharmaCompass.
Buvacaina Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Buvacaina GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Buvacaina GMP manufacturer or Buvacaina GMP API supplier for your needs.
A Buvacaina CoA (Certificate of Analysis) is a formal document that attests to Buvacaina's compliance with Buvacaina specifications and serves as a tool for batch-level quality control.
Buvacaina CoA mostly includes findings from lab analyses of a specific batch. For each Buvacaina CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Buvacaina may be tested according to a variety of international standards, such as European Pharmacopoeia (Buvacaina EP), Buvacaina JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Buvacaina USP).
